Mvasi

Pharma

With biosim sales up 16%, Amgen expects another boost in 2025

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion by the end of the decade.

Kevin Dunleavy Feb 5, 2025 11:28am

Pfizer, Amgen entering 'golden age' for biosimilars: analyst

Aug 5, 2020 9:50am